Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review
Cureus · 07.02.2024
DOI: 10.7759/cureus.53816 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 07.02.2024. Verfasst von Fatima AlKindi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tawam Hospital, Al Ain, ARE. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Tawam Hospital, Al Ain, ARE.
- Seha Kidney Care, Tawam Hospital, Al Ain, ARE.
- Department of Internal Medicine, College of Medicine and Health Sciences, Al Ain, ARE.
- Department of Oncology, Tawam Hospital, Al Ain, ARE.
- Division of Endocrinology, Tawam Hospital, Al Ain, ARE.
Zitieren
APA
AlKindi, F., Boobes, Y., Shalwani, F., Ansari, J., & Almazrouei, R. (2024). Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review. Cureus. https://doi.org/10.7759/cureus.53816
Vancouver
AlKindi F, Boobes Y, Shalwani F, Ansari J, Almazrouei R. Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review. Cureus. 2024. doi:10.7759/cureus.53816
BibTeX
@article{AlKindi2024,
author = {AlKindi, Fatima and Boobes, Yousef and Shalwani, Fatima and Ansari, Jawaher and Almazrouei, Raya},
title = {Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review},
journal = {Cureus},
year = {2024},
doi = {10.7759/cureus.53816}
}
EUVIMED